复方雪莲胶囊联合塞来昔布治疗强直性脊柱炎的临床研究

Clinical study on Compound Xuelian Capsules combined with celecoxib in treatment of ankylosing spondylitis

目的研究复方雪莲胶囊联合塞来昔布胶囊治疗强直性脊柱炎的临床疗效。方法选取2018年6月—2019年6月在郑州大学第一附属医院(惠济院区)治疗的100例强直性脊柱炎患者为研究对象,将所有患者随机分为对照组和治疗组,每组各50例。对照组患者口服塞来昔布胶囊,1粒/次,1次/d。治疗组在对照组基础上口服复方雪莲胶囊,2粒/次,2次/d。两组患者持续治疗2个月。观察两组的临床疗效,比较两组的临床症状缓解时间、巴氏强直性脊柱炎疾病活动指数(BASDAI)评分和巴氏强直性脊柱炎功能指数(BASFI)评分、枕墙距、生活质量综合评定问卷(GQOLI-74)评分、血清炎性因子水平。结果治疗后,对照组和治疗组的总有效率分别为78.00%、96.00%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者下腰背疼痛、外周关节肿胀、外周关节疼痛缓解时间显著短于对照组(P<0.05)。治疗后,两组患者BASDAI评分、BASFI评分、枕墙距均显著降低,生活质量综合评定问卷(GQOLI-74)评分显著升高(P<0.05),且治疗后治疗组BASDAI评分、BASFI评分、枕墙距低于对照组,GQOLI-74评分高于对照组(P<0.05)。治疗后,两组血清C反应蛋白(CRP)、白细胞介素-1β(IL-1β)和肿瘤坏死因子-α(TNF-α)水平显著降低(P<0.05);并且治疗组血清CRP、IL-1β和TNF-α水平降低较明显(P<0.05)。结论复方雪莲胶囊联合塞来昔布胶囊治疗强直性脊柱炎具有较好的临床疗效,能够改善临床症状,提高患者生活质量,降低血清炎性因子水平,值得在临床上推广应用。

Objective To study the efficacy of Compound Xuelian Capsules combined with Celecoxib Capsules in treatment of ankylosing spondylitis. Methods Patients(100 cases) with ankylosing spondylitis in the First Affiliated Hospital of Zhengzhou University(Huiji Campus) from June 2018 to June 2019 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were po administered with Celecoxib Capsules, 1 grains/time, once daily. Patients in the treatment group were po administered with Compound Xuelian Capsules on the basis of the control group, 2 grains/time, twice daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacies were evaluated, and clinical symptom remission time, BASDAI score, BASFI score, sleeper wall distance and GQOLI-74 score, and the levels of serum inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 78.00% and 96.00%, respectively, and there was difference between two groups(P < 0.05). After treatment, the remission time of peripheral joint pain, low back pain and peripheral joint swelling in the two groups was significantly shorter than that in the control group(P < 0.05). After treatment, BASDAI scores, BASFI scores, and occipital wall distance in the two groups were significantly decreased, but GQOLI-74 scores in two groups were significantly increased(P < 0.05). And the BASDAI score, BASFI score and occipital wall distance of the treatment group were lower than those of the control group, but the GQOLI-74 score of the treatment group was higher than that of the control group(P < 0.05). After treatment, the serum levels of CRP, IL-1β, and TNF-α in the two groups were significantly decreased(P < 0.05). And the serum levels of CRP, IL-1β, and TNF-α in the treatment group were significantly lower than those in the control group(P < 0.05). Conclusion Compound Xuelian Capsules combined with Celecoxib Capsules has clinical curative effect in treatment of ankylosing spondylitis, can improve the clinical symptoms and the quality of life of patients, reduce the serum level of inflammatory factors, which is worthy of clinical application.